ReviewDermatologic therapy2020
Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.
Review in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04699097 (Azitromycin Use in COVID-19 Positive Pediatric Patients; Effect on Ventricle Repolarization), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Azitromycin Use in COVID-19 Positive Pediatric Patients; Effect on Ventricle Repolarization
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis.Cardiology journal · 2022Pooled it
- Supply Chain Vulnerabilities in First-Line Treatments for Sexually Transmitted Infections: Implications for U.S. Public Health Preparedness.medRxiv : the preprint server for health sciences · 2026Article
- Evaluation and Optimization of Azithromycin Removal by Raw and Alkali-Modified Peanut Shells Using Taguchi-Based Experimental Design Approach.Water environment research : a research publication of the Water Environment Federation · 2026Article
- The impact of the COVID-19 pandemic on the antibiotic consumption and resistance in Montenegro.European journal of public health · 2025Article
- Prevalence of azithromycin resistance after the COVID-19 era in clinical bacterial isolates from a tertiary care hospital in Gurugram, India.Frontiers in microbiology · 2025Article
- Post-COVID-19 neuropsychiatric manifestations: a suggested therapeutic approach to 'long COVID' with azithromycin.Epidemiology and infection · 2023Article
- Article
- Antihistamines as an early treatment for Covid-19.Heliyon · 2023Article
- A pandemic within a pandemic? Admission to COVID-19 wards in hospitals is associated with increased prevalence of antimicrobial resistance in two African settings.Annals of clinical microbiology and antimicrobials · 2023Article
- Factors Associated with the Antibiotic Treatment of Children Hospitalized for COVID-19 during the Lockdown in Serbia.International journal of environmental research and public health · 2022Article
- Effects of azithromycin on ventricular repolarization in children with COVID-19.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2022Article
- Self-Medication with Antibiotics during COVID-19 in the Eastern Mediterranean Region Countries: A Review.Antibiotics (Basel, Switzerland) · 2022Review
- Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment.Archivos de cardiologia de Mexico · 2021Article
- COVID-19: potential therapeutics for pediatric patients.Pharmacological reports : PR · 2021Review
- Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations.Chemical physics letters · 2021Article
- The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.Computational biology and chemistry · 2021Article
- Repurposing of antibiotics for clinical management of COVID-19: a narrative review.Annals of clinical microbiology and antimicrobials · 2021Review
- Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.Pulmonary pharmacology & therapeutics · 2021Observational
- Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.Dermatologic therapy · 2020Review
- What we have learned from the COVID-19 pandemic: Time to think outside the box, maybe far outside.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID-19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu-like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID-19 infection. There is one clinical trial initiated, the individually randomized, telemedicine-based, "Azithromycin for COVID-19 Treatment in Outpatients Nationwide" based at the University of California San Francisco. This placebo-controlled trial is designed to determine the efficacy of a single 1.2-g dose of oral azithromycin to prevent COVID-19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID-19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for 4 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.